Association between NFKB1 −94ins/del ATTG Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis

Table 1

Main characteristics of these studies included in this meta-analysis.

First Author	Year	Ethnicity	Genotyping method	SC	Genotyping cases			Controls			Cancer type	HWE
					ins/ins	ins/del	del/del	ins/ins	ins/del	del/del
Lin [16]	2006	Asian	PCR-RFLP	HB	59	103	50	43	100	58	OSCC	0.993
Riemann [17]	2007	Caucasian	Pyrosequencing	HB	88	124	30	118	141	48	Bladder cancer	0.586
Bu [18]	2007	Caucasian	PCR-RFLP	HB	67	84	34	116	255	67	Melanoma	<0.001
Lewander [11]	2007	Caucasian	PCR-RFLP	HB	63	323	81	116	256	67	Colorectal cancer	<0.001
		Asian	PCR-RFLP	HB	50	101	42	113	266	79	Colorectal cancer	<0.001
Lo [19]	2008	Asian	PCR-RFLP	HB	62	89	31	20	62	34	Gastric cancer	0.361
Zhang [20]	2009	Asian	PCR-RFLP	HB	46	57	14	44	68	31	Prostate cancer	0.624
Burnik [21]	2009	Caucasian	PCR-RFLP	HB	18	30	2	30	58	12	GNT	0.047
Zhou [22]	2009	Asian	PCR-RFLP	HB	74	67	22	71	90	42	NC	0.177
Tang [23]	2009	Asian	PCR-RFLP	HB	89	92	26	74	108	46	Bladder cancer	0.565
Andersen [24]	2010	Caucasian	Taqman	PB	121	195	62	307	347	102	Colorectal cancer	0.801
Zhou [25]	2010	Asian	PCR-RFLP	HB	108	105	20	135	166	64	CSCC	0.297
Fan [26]	2011	Asian	PCR-RFLP	HB	78	84	17	76	103	44	Ovarian cancer	0.396
Lin [27]	2012	Asian	Taqman	HB	116	246	100	81	271	168	OSCC	0.099
Vangsted [28]	2012	Caucasian	Taqman	PB	110	163	55	665	778	253	Multiple myeloma	0.303
Cai [10]	2012	Asian	Taqman	HB	401	473	153	379	562	153	Renal cell Carcinoma	0.015
Huo [29]	2013	Asian	MassARRAY	HB	83	82	22	71	103	47	Ovarian cancer	0.399
Cheng [30]	2013	Asian	Taqman	HB	42	64	29	81	271	168	HC	0.099
Mohd Suzairi [31]	2013	Asian	PCR-RFLP	HB	35	127	75	16	138	83	Colorectal cancer	<0.001
Kopp [32]	2013	Caucasian	Taqman	PB	128	152	54	109	161	64	Prostate cancer	0.741
Li [12]	2013	Asian	Taqman	HB	189	269	151	223	324	93	Bladder cancer	0.156

GNT: Gastroenteropancreatic neuroendocrine tumors; OSCC: oral squamous cell carcinoma; CSCC: cervical squamous cell carcinoma; NC: nasopharyngeal carcinoma; HC: hepatocellular carcinoma; HB: hospital-based study; PB: population-based study; SC: source of controls; HWE: Hardy Weinberg equilibrium.